wikimedia
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
Graphs
1
Q38525856-81664DC8-6C38-4066-93AE-CB2FF81454CD
Q38525856-81664DC8-6C38-4066-93AE-CB2FF81454CD
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38525856-81664DC8-6C38-4066-93AE-CB2FF81454CD
Strategies to overcome resistance to tyrosine kinase inhibitors in non-small-cell lung cancer.
P2860
Q38525856-81664DC8-6C38-4066-93AE-CB2FF81454CD
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38525856-81664DC8-6C38-4066-93AE-CB2FF81454CD
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
0d39f18cec37c8f29fb3d9ccef05d44020b5acdf
P2860
A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib.